AbbVie Expects Two Of Its Biggest Drugs To Bring In $27 Billion In 2027. And Neither One Is Humira.Investors Business Daily • 02/02/24
AbbVie Posts Revenue Beat as Humira Sales Tumble. Other Immunology Drugs Are Selling.Barrons • 02/02/24
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024InvestorPlace • 01/31/24
Allergan Aesthetics Releases "Decoding the Future of Aesthetic Individuality" Exploring the Power of Self-ExpressionPRNewsWire • 01/31/24
Unveiling AbbVie (ABBV) Q4 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 01/30/24
2 High-Yield Healthcare Stocks to Buy With Both Hands and 1 to Avoid for NowThe Motley Fool • 01/28/24
CEREVEL THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CEREPRNewsWire • 01/26/24
Allergan Aesthetics Showcases Commitment to Individuality, Innovation, and Integrity at IMCAS World Congress 2024PRNewsWire • 01/25/24
Instead Of Buying A Rolex, I'm Investing $20,000 In These 2 Stocks, Yielding Up To 7%Seeking Alpha • 01/24/24
Allē by Allergan Aesthetics is the Leading Aesthetics Loyalty Rewards Program in the U.S.PRNewsWire • 01/23/24